XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
S
S

Sanofi


خبر

Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital

Cybersecurity firm Semperis raises $125 mln from JP Morgan, Hercules Capital June 20 (Reuters) - Cybersecurity software firm Semperis said on Thursday it has raised $125 million in financing from J.P. Morgan and Hercules Capital, which would fund research and development at the company and help expand its global footprint. The financing comes two years after Semperis raised $200 million in a Series C round led by private equity firm KKR KKR.N .
J
S

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

Industry groups back drugmakers' appeal in Zantac cancer lawsuits By Brendan Pierson June 20 (Reuters) - A bid by GSK GSK.L and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.
G
P
S

US FDA approves Merck's pneumococcal vaccine for adults

US FDA approves Merck's pneumococcal vaccine for adults June 17 (Reuters) - The U.S. Food and Drug Administration approved Merck's MRK.N next-generation vaccine to protect adults against pneumococcal disease, according to a letter on the health regulator's website on Monday. Reporting by Bhanvi Satija, Sneha S K and Puyaan Singh in Bengaluru; Editi
P
S

Innate Pharma Shares Updated Results From The Sanofi Developed Blood Cancer Phase 1/2 Sar443579/Iph6101 Trial

BRIEF-Innate Pharma Shares Updated Results From The Sanofi Developed Blood Cancer Phase 1/2 Sar443579/Iph6101 Trial June 17 (Reuters) - Innate Pharma SA IPH.PA : INNATE PHARMA SHARES UPDATED RESULTS FROM THE SANOFI DEVELOPED BLOOD CANCER PHASE 1/2 SAR443579/IPH6101 TRIAL Source text for Eikon: ID:nBwtnrpca Further company coverage: [IPH.PA SASY.PA]
S

Probiotics maker Seed Health explores $1 billion sale, sources say

Probiotics maker Seed Health explores $1 billion sale, sources say By Abigail Summerville and Anirban Sen June 12 (Reuters) - The owners of Seed Health, one of the few profitable U.S. biotechnology startups, are exploring a sale of the probiotics maker that could value it at more than $1 billion, according to people familiar with the matter. Seed, which is owned by its founders and co-chief executives Ara Katz and Raja Dhir, as well as venture capital investors, is soliciting acquisition offers
S

New Pharma will crowd out Big Pharma

BREAKINGVIEWS-New Pharma will crowd out Big Pharma The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, June 11 (Reuters Breakingviews) - Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N , $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O .
A
G
N
P
R
R
S
V

GSK asks to appeal Delaware ruling allowing Zantac cases to go forward

UPDATE 1-GSK asks to appeal Delaware ruling allowing Zantac cases to go forward Recasts headline, paragraphs 1-4 with appeal petition By Brendan Pierson June 10 (Reuters) - GSK GSK.L and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 lawsuits claiming that heartburn drug Zantac causes cancer to go forward.
G
P
S

Latest trial over Zantac cancer claims called off as plaintiff drops case

Latest trial over Zantac cancer claims called off as plaintiff drops case By Brendan Pierson June 10 (Reuters) - A woman who claimed in a lawsuit that GSK's GSK.L discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the company announced. GSK said in a statement that it did not settle with the woman, Eugenia Kasza.
G
P
S

Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial

BUZZ-Moderna rises as COVID/flu combo vaccine shows superiority over separate shots in trial ** Shares of Moderna MRNA.O rise 1.81% to $153.75 premarket ** Co says its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response when compared to separate shots in a late-stage trial ** The combination vacci
G
S

Moderna COVID/flu combo vaccine superior to separate shots in trial

Moderna COVID/flu combo vaccine superior to separate shots in trial By Patrick Wingrove June 10 (Reuters) - Moderna MRNA.O said on Monday its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial. In the study, the combination using messenger RNA technology generated greater antibodies than currently marketed traditional flu vaccines and Moderna's
S

What to know about bird flu in dairy cows and the risk to humans

EXPLAINER-What to know about bird flu in dairy cows and the risk to humans Adds new details on affected states in paragraphs 1-2, details on a fatal case in Mexico By Julie Steenhuysen CHICAGO, June 7 (Reuters) - The outbreak of bird flu in U.S. dairy cows has now been confirmed in Minnesota and Iowa, bringing to 11 the total number of affected states, which have been encouraged to ramp up testing efforts at the request of government officials.
G
S

EuroAPI appoints mediator to help restructure pile of debt, shares drop

UPDATE 1-EuroAPI appoints mediator to help restructure pile of debt, shares drop Updates with market reaction segment By Nathan Vifflin June 7 (Reuters) - French pharmaceutical supplier EuroAPI EAPI.PA has engaged a third-party mediator, known as a mandataire ad hoc, to handle financing discussions with creditors as it struggles to serve a growing pile of debt.
S

Column: Will Zantac ruling make Delaware a mass torts magnet?

Column: Will Zantac ruling make Delaware a mass torts magnet? The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel June 3 (Reuters) - If you are mass torts lawyer, you should be paying attention to a trend that has emerged in litigation over the discontinued heartburn medication Zantac. On Friday, as my Reuters colleague Brendan Pierson reported , a Delaware Superior Court judge ruled that nearly 75,000 lawsuits alleging that Zantac causes cancer can mo
G
P
S

Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3

BRIEF-Sanofi Says Sarclisa Is First Anti-Cd38 To Improve Progression-Free Survival For Diagnosed Transplant-Ineligible Multiple Myeloma In Phase 3 June 3 (Reuters) - Sanofi SA SASY.PA : REG-PRESS RELEASE: ASCO: SARCLISA IS FIRST ANTI-CD38 TO SIGNIFICANTLY IMPROVE PROGRESSION-FREE SURVIVAL IN COMBINATION WITH VRD FOR NEWLY DIAGNOSED TRANSPLANT-INELI
S

Investors prescribe harsh medicine for GSK’s boss

BREAKINGVIEWS-Investors prescribe harsh medicine for GSK’s boss The author is a Reuters Breakingviews columnist. The opinions expressed are her own. Refiles to change ambiguous ‘them’ in fifth paragraph to ‘investors’. By Yawen Chen LONDON, June 3 (Reuters Breakingviews) - GSK GSK.L investors are having a panic attack. Jittery shareholders of the $93 billion British drugmaker on Monday wiped $9 billion off its value after a U.S.
A
G
S

Deutsche Post Group - Dhl Supply Chain Partners with Sanofi

BRIEF-Deutsche Post Group - Dhl Supply Chain Partners with Sanofi June 3 (Reuters) - DEUTSCHE POST AG DHLn.DE : DHL SUPPLY CHAIN EXPANDS PHARMA LOGISTICS OPERATIONS IN FRANCE DHL SUPPLY CHAIN HAS EXPANDED ITS SPECIALIZED LOGISTICS SERVICES FOR THE LIFE SCIENCES AND HEALTHCARE SECTOR IN FRANCE THROUGH A LONG-TERM STRATEGIC PARTNERSHIP WITH SANOFI DH
S

GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed

UPDATE 2-GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed Updates shares and adds more analysts in paragraphs 7-11 By Yadarisa Shabong and Maggie Fick June 3 (Reuters) - Shares of GSK GSK.L dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.
G
P
S

Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT

BRIEF-Sanofi Pushes Ahead With 20 Bln Euros Consumer Healthcare Spin-Off - FT June 2 (Reuters) - SANOFI PUSHES AHEAD WITH €20BN CONSUMER HEALTHCARE SPIN-OFF - FT GOLDMAN SACHS, MORGAN STANLEY WILL WORK WITH BNP PARIBAS & BANK OF AMERICA ON SALE; POTENTIAL FLOAT EXPECTED TO TAKE PLACE AS SOON AS END OF YEAR - FT Source text: https://on.ft.com/4bXj
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

UPDATE 2-Delaware judge lets more than 70,000 Zantac lawsuits go forward Adds detail from opinion in paragraphs 3-4 By Brendan Pierson June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N
G
P
S

Delaware judge lets more than 70,000 Zantac lawsuits go forward

Delaware judge lets more than 70,000 Zantac lawsuits go forward June 1 (Reuters) - A Delaware judge has allowed more than 70,000 lawsuits over discontinued heartburn drug Zantac to go forward, ruling that expert witnesses can testify in court that the drug may cause cancer. The ruling on Friday by Judge Vivian Medinilla of the Delaware Superior Court in Wilmington is a setback for former Zantac makers GSK GSK.L , Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, which had argued that the e
G
P
S



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔